Epidemiology of Sudden Cardiac Death in Patients with Heart Failure

Heart Failure Clinics

Volumn 7, Issue 2, 2011, Pages 147-155

  Houmsse, Mahmoud ^a   Franco, Veronica ^b   Abraham, William T ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Ejection fraction; Heart failure; Predictor; Sudden cardiac death

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; METOPROLOL; PROCAINAMIDE; VALSARTAN;

ACUTE HEART INFARCTION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DISEASE COURSE; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTIVE CARDIOMYOPATHY; REVIEW; SUDDEN DEATH; SURVIVAL RATE; SYSTOLIC DYSFUNCTION;

DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 79952827005     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2010.12.008     Document Type: Review

References (78)

1. Jessup M., Abraham W.T., Casey D., et al. 2009 Focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:1343-1382.
2. Lechat P., Brunhuber K.W., Hofmann R., et al. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999, 353:9-13.
3. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
4. Pitt B., Williams G., Remme W., et al. Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study (EPHESUS trial). Cardiovasc Drugs Ther 2001, 15:79-87.
5. Garg R.G., Yusuf S. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450-1456.
6. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
7. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992, 327:669-677.
8. Rankin A.C., Cobbe S.M. Arrhytmias and sudden death in heart failure: can we prevent them?. Heart failure in clinical practice 1996, 189-205. Martin Dunitz Ltd, London. J.J. McMurray, J.G. Cleland (Eds.).
9. Goldstein S. The changing epidemiology of sudden death in heart failure. Curr Heart Fail Rep 2004, 1:93-97.
10. Chugh S.S., Jui J., Gunson K., et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004, 44:1268-1275.
11. Myerburg R.J., Castellanos A. Emerging paradigms of the epidemiology and demographics of sudden cardiac arrest. Heart Rhythm 2006, 3(2):235-239.
12. de Vreede Swagemakers J.J., Gorgels A.P., Dubois-Arbouw W.I., et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997, 30:1500-1505.
13. Myerburg R.J. Scientific gaps in the prediction and prevention of sudden cardiac death. J Cardiovasc Electrophysiol 2002, 13:709-723.
14. Zheng Z.J., Croft J.B., Giles W.H., et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001, 104:2158-2163.
15. Cobb L.A., Fahrenbruch C.E., Olsufka M., et al. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 2002, 288:3008-3013.
16. Escobedo L.G., Zack M.M. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 1996, 93:2033-2036.
17. Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993, 119:1187-1197.
18. Zipes D.P., Cam J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2006, 48:1064-1108.
19. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update. Circulation 2006, 113:e85-e151.
20. American Heart Association 2002 Heart and stroke statistical update 2001, American Heart Association, Dallas (TX).
21. American Cancer Society Surveillance research, cancer facts and figures 2001 2001, American Cancer Society, Inc, Atlanta (GA).
22. Statistical Abstract of the United States: 2001. U.S. Census Bureau; 2001.
23. Gillum R.F. Sudden cardiac death in Hispanic Americans and African Americans. Am J Public Health 1997, 87:1461-1466.
24. Becker L.B., Han B.H., Meyer P.M., et al. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project. N Engl J Med 1993, 329:600-606.
25. Mozaffarian D., Anker S.D., Anand I., et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007, 116:392-398.
26. Aaronson K.D., Schwartz J.S., Chen T.M., et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95:2660-2667.
27. Brophy J.M., Dagenais G.R., McSherry F., et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004, 116:300-304.
28. Goldberg L.R., Jessup M. Stage B heart failure management of asymptomatic left ventricular systolic dysfunction. Circulation 2006, 113:2851-2860.
29. Buxton A.E., Lee K.L., Fisher J.D., et al. Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999, 341:1882-1890.
30. Moss A.J., Hall W.J., Cannom D.S., et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933-1940.
31. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
32. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350:2151-2158.
33. Packer D.L., Bardy G.H., Worley S.J., et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986, 57:563-570.
34. Rosenqvist M., Lee M.A., Moulinier L., et al. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol 1990, 16:1467-1474.
35. Gillette P.C., Smith R.T., Garson A., et al. Chronic supraventricular tachycardia: a curable cause of congestive cardiomyopathy. JAMA 1985, 253:391-392.
36. Wu E.B., Chia H.M., Gill J.S. Reversible cardiomyopathy after radiofrequency ablation of lateral free-wall pathway-mediated incessant supraventricular tachycardia. Pacing Clin Electrophysiol 2000, 23:1308-1310.
37. Ott P., Kelly P.A., Mann D.E., et al. Tachycardia-induced cardiomyopathy in a cardiac transplant recipient: treatment with radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1995, 6:391-395.
38. Harrigan J.T., Kangos J.J., Sikka A., et al. Successful treatment of fetal congestive heart failure secondary to tachycardia. N Engl J Med 1981, 304:1527-1529.
39. Manolis A.G., Katsivas A.G., Lazaris E.E., et al. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 1998, 2:71-76.
40. Grogan M., Smith H.C., Gersh B.J., et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992, 69:1570-1573.
41. Nerheim P., Birger-Botkin S., Piracha L., et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004, 110:247-252.
42. Cohn J.N., Johnson G. Heart failure with normal ejection fraction: the V-HEFT study. Circulation 1990, 81(2 Suppl):III48-III53.
43. Al-Khatib SM, Shaw LK, O'Connor CM, et al. Sudden cardiac death in patients with diastolic heart failure [abstract]. Circulation 2006;114:II405.
44. Maron B.J., Shirani J., Poliac L.C., et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276:199-204.
45. Maron B.J., Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000, 102:858-864.
46. Kofflard M.J., Ten Cate F.J., van der Lee C., et al. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003, 41:987-993.
47. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287:1308-1320.
48. Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989, 13:1283-1288.
49. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365-373.
50. Primo J., Geelen P., Brugada J., et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998, 31:1081-1085.
51. Mckenna W.J., Deanfield J., Faruqui A., et al. Prognosis in hypertrophic cardiomyopathy. Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981, 47:532-538.
52. Maron B.J., Lipson L.C., Roberts W.C., et al. "Malignant" hypertrophic cardiomyopathy: Identification of a subgroup of families with unusually frequent premature deaths. Am J Cardiol 1978, 41:1133-1140.
53. Priori S.G., Aliot E., Blomstrom-Lundqvist C., et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001, 22:1374-1450.
54. Maron B.J., Savage D.D., Wolfson J.K., et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981, 48:252-257.
55. Sadoul N., Prasad K., Elliott P.M., et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96:2987-2991.
56. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy and risk of sudden cardiac death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785.
57. Marian A.J., Roberts R. Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998, 9:88-99.
58. Spirito P., Seidman C.E., McKenna W.J., et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775-785.
59. Rivenes S.M., Kearney D.L., O'Brian Smith E., et al. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 2000, 102:876-882.
60. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997, 96:509-516.
61. Stanek B., Frey B., Huelsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001, 38:436-442.
62. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 105:2392-2397.
63. Huikuri H.V., Tapanainen J.M., Lindgren K., et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003, 42:652-658.
64. Solomon S.D., Zelenkofske S., McMurray J.J., for the Valsartan in Acute Myocardial Infarction, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005, 352:2581-2588.
65. Ottervanger J.P., Ramdat Misier A.R., Dambrink J.H., et al. Mortality in patients with left ventricular ejection fraction <30% after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 2007, 100:793-797.
66. Hohnloser S.H., Gersh B.J. Changing late prognosis of acute myocardial infarction: impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator. Circulation 2003, 107:941-946.
67. Goldberger J.J., Cain M.E., Hohnloser S.H., et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008, 118:1497-1518.
68. Wilber D.J., Zareba W., Hall W.J., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004, 109:1082-1084.
69. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter defibrillator after acute myocardial infarction. DINAMIT Investigators. N Engl J Med 2004, 351:2481-2488.
70. Steinbeck G. A randomized study of defibrillator implantation early after myocardial infarction in high-risk patients on optimal medical therapy. Paper presented at American College of Cardiology 2009 Scientific Sessions. Orlando: March 31, 2009.
71. Bardy G.H., Lee K.L., Mark D.B., et al. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med 2008, 358:1793-1804.
72. Uther J.B., Richards J.B., Dennis A.R., et al. The prognostic significance of programmed ventricular stimulation after myocardial infarction. Circulation 1987, 75:1161-1165.
73. Denniss A.R., Richards D.A., Cody D.V., et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986, 74:731-745.
74. Bhandarhi I.A., Hong R., Kotelski A., et al. Prognostic significance of programmed ventricular stimulation in survivors of acute myocardial infarction. Br Heart J 1989, 61:410-416.
75. Raviele A., Bongiorni M.G., Brignole M., et al. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment: the BEtablocker STrategy plus ICD trial. Europace 2005, 7:327-337.
76. Goldberger J.J., Passman R. Implantable cardiovertor-defibrillator therapy after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2001-2005.
77. Goldenberg I., Moss A.J., McNitt S., for the MADIT-II Investigators, et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006, 47:1811-1817.
78. Saxon L.A., Bristow M.R., Boehmer J., et al. Predictors of sudden cardiac death and appropriate shock in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial. Circulation 2006, 114:2766-2772.